Liana Gillooly

Liana Sananda Gillooly is a prominent figure in the psychedelic research and advocacy space, currently serving as the Development Officer at the Multidisciplinary Association for Psychedelic Studies (MAPS). Her work and passion revolve around advancing psychedelic research, drug policy reform, and ethical business practices in the emerging psychedelic industry.

Professional Background

Liana's career has been diverse and impactful:

• Development Officer at MAPS: In this role, she leads fundraising efforts to support MAPS' research, including Phase III FDA trials for MDMA-assisted therapy for PTSD.2

• Co-founder and Board Chair of North Star: She helped establish North Star, the first trade association for the psychedelic field, focusing on ethical stewardship of psychedelic commercialization.12

• Co-founder of Auryn Project: This organization is involved in psychedelic advocacy and policy work.2

• Previous Roles: Liana has worked as a gallerist, art curator, event producer, and held management positions at Greenpeace and Essential Living Foods.3

Advocacy and Expertise

Liana is known for her dedication to several causes:

• Drug Policy Reform: She is a lifelong advocate for drug policy reform and ending the war on drugs.12

• Social Justice: Her work extends to social justice issues and environmental protection.1

• Psychedelic Business Ethics: Liana is passionate about aligning purpose and impact in the psychedelic field, emphasizing ethical business practices.4

• Public Speaking: She has lobbied Congress, lectured MBA students, and given a TEDx talk.1

Personal Interests and Skills

Beyond her professional work, Liana has diverse personal interests:

• Meditation: She is an experienced Vipassana meditator.1

• Death Midwifery: Liana is trained as a death midwife.1

• Immersive Art: She has involvement in immersive art projects.1

Liana Sananda Gillooly's multifaceted background and dedication to ethical psychedelic research and policy make her a significant figure in the field, bridging the gap between advocacy, research, and responsible business practices in the emerging psychedelic industry.